Publications by authors named "Michaela Lefaivre"
Article Synopsis
- PVSRIPO, an oncolytic polio-rhinovirus recombinant, shows potential effectiveness against recurrent glioblastoma and has received breakthrough therapy designation from the FDA.
- A new anti-CD155 antibody has been validated for detecting the poliovirus receptor CD155 in glioblastoma tissue samples, crucial for ongoing clinical development of PVSRIPO immunotherapy.
- The developed assay confirms that CD155 is widely expressed in glioblastoma cells, correlating with their susceptibility to infection and destruction by PVSRIPO, which is key for future treatment strategies.
Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detection of MIB-1, Tenascin C, CD34, VEGF, and CA IX may represent objective markers of post-operative survival (Progression Free and Overall Survival; PFS, OS) in these patients. Intracranial ependymomas from patients aged 22 years or less were studied.
View Article and Find Full Text PDF